Preview Mode Links will not work in preview mode

This Week in Cardiology

Aug 25, 2023

GLP-1 agonists in HFpEF, DOACs for subclinical AF, renal denervation, and the matter of remaining in the profession are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

I. Obesity and HFpEF

GLP-1 Agonists in HFpEF With Obesity: Are We There Yet?

Wegovy Scores HFpEF Benefits in People With Obesity

- Semaglutide in Obese Patients With HFpEF

- Rationale/Protocol Paper

II. DOAC for Subclinical AF

- NOAH-AFNET 6 Rationale/Protocol

- NOAH-AFNET 6 Trial Results

III. Renal Denervation

ReCor Renal Denervation System Safe, Effective: FDA Panel

FDA Panel Split on Efficacy of Spyral Renal Denervation


IV. Maintenance of Certification

As MOC Debate Heats Up, Cardiology Societies Weigh In


Mandrola's 5 Things to Look for at the Upcoming ESC 2023

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact: